

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2019

Vol. 47, No. 6

CONTENTS

COMMENTARY

- Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. *Dennis A. Smith and Malcolm Rowland* **665**

MINIREVIEW

- Overview of the Components of Cardiac Metabolism. *Elizabeth A. Hausner, Susan A. Elmore, and Xi Yang* **673**

ARTICLES

- Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate–Peroxisome Proliferator-Activated Receptor- γ Activation. *Feng Xu, Liang Zhu, Chaoqun Qian, Junjie Zhou, Donghao Geng, Ping Li, Wenjing Xuan, Fangge Wu, Kaijing Zhao, Weimin Kong, Yuanyuan Qin, Limin Liang, Li Liu, and Xiaodong Liu* **556**
- Rolapitant Is a Reversible Inhibitor of CYP2D6. *Sarah M. Glass, Sabrina M. Leddy, Michael C. Orwin, Garret P. Miller, Kyle A. Furge, and Laura Lowe Furge* **567**
- Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity. *Yu-Jie Chen, Jian Zhang, Ping-Ping Zhu, Xian-Wen Tan, Qiu-Hong Lin, Wen-Xia Wang, Shan-Shan Yin, Ling-Zhi Gao, Ming-Ming Su, Chang-Xiao Liu, Liang Xu, Wei Jia, Irina F. Sevrioukova, and Ke Lan* **574**
- Maternal Plasma L-Carnitine Reduction During Pregnancy Is Mainly Attributed to OCTN2-Mediated Placental Uptake and Does Not Result

in Maternal Hepatic Fatty Acid β -Oxidation Decline. *Mengru Bai, Qingquan Zeng, Yingchun Chen, Mingyang Chen, Ping Li, Zhiyuan Ma, Dongli Sun, Hui Zhou, Caihong Zheng, Su Zeng, and Huidi Jiang* **582**

- Developmental Expression of the Cytosolic Sulfotransferases in Human Liver. *Sarah Dubaisi, Joseph A. Caruso, Roger Gaedigk, Carrie A. Vyhldal, Philip C. Smith, Ronald N. Hines, Thomas A. Kocarek, and Melissa Runge-Morris* **592**

- An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials. *C.J. Henderson, Y. Kapelyukh, N. Scheer, A. Rode, AW. McLaren, A.K. MacLeod, D. Lin, J. Wright, L.A. Stanley, and C.R. Wolf* **601**

- Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. *Pramod C. Nair, Ross A. McKinnon, and John O. Miners* **616**

- Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPSCs. *Sayaka Deguchi, Tomoki Yamashita, Keisuke Igai, Kazuo Harada, Yukiko Toba, Kazumasa Hirata, Kazuo Takayama, and Hiroyuki Mizuguchi* **632**

- RNA Editing Enzymes Modulate the Expression of Hepatic CYP2B6, CYP2C8, and Other Cytochrome P450 Isoforms. *Kaori Nozaki, Masataka Nakano, Chika Iwakami, Tatsuki Fukami, and Miki Nakajima* **639**

- Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy. *Philippe B. Pierrillas, Emilie Henin, Kathryn Ball, Julien Ogier, Magali Amiel, Laurence Kraus-Berthier,*

Downloaded from dmd.aspetjournals.org at ASPET Journals on January 17, 2021

Continued on next page

Marylore Chenel, François Bouzom, and Michel Tod **648**

☐ Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors. Chongzhuang Tang, Zhaoqiang Chen, Xiaojian Dai, Weiliang Zhu, Dafang Zhong, and Xiaoyan Chen **657**

ERRATUM

Correction to: Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs. **689**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Comparison of the active site starting position to egress position in channel 2c for rolapitant egress. See the article by Glass et al., ([dx.doi.org/10.1124/dmd.118.085928](https://doi.org/10.1124/dmd.118.085928)).